Show simple item record

dc.creatorMaría Teresa González Garza y Barrón
dc.creatorJorge Eugenio Moreno Cuevas
dc.date2016
dc.date.accessioned2018-10-18T15:34:07Z
dc.date.available2018-10-18T15:34:07Z
dc.identifier.issn2780240
dc.identifier.doi10.1155/2016/6597970
dc.identifier.urihttp://hdl.handle.net/11285/630267
dc.descriptionThere is a need for new noninvasive biomarkers (NIBMs) able to assess cholestasis and fibrosis in chronic cholestatic liver diseases (CCLDs). Tumorigenesis can arise from CCLDs. Therefore, autoantibodies to tumor-associated antigens (TAA) may be early produced in response to abnormal self-antigen expression caused by cholestatic injury. Vascular endothelial growth factor receptor-3 (VEGFR-3) has TAA potential since it is involved in cholangiocytes and lymphatic vessels proliferations during CCLDs. This study aims to detect autoantibodies directed at VEGFR-3 during bile duct ligation- (BDL-) induced cholestatic injury in rat sera and investigate whether they could be associated with traditional markers of liver damage, cholestasis, and fibrosis. An ELISA was performed to detect anti-VEGFR-3 autoantibodies in sera of rats with different degree of liver injury and results were correlated with aminotransferases, total bilirubin, and the relative fibrotic area. Mean absorbances of anti-VEGFR-3 autoantibodies were significantly increased from week one to week five after BDL. The highest correlation was observed with total bilirubin (R2 = 0.8450, P = 3.04e - 12). In conclusion, anti-VEGFR-3 autoantibodies are early produced during BDL-induced cholestatic injury, and they are closely related to cholestasis, suggesting the potential of anti-VEGFR-3 autoantibodies as NIBMs of cholestasis in CCLDs and justifying the need for further investigations in patients with CCLD. Copyright © 2016 Florent Duval et al.
dc.languageeng
dc.publisherHindawi Limited
dc.relationhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84964703733&doi=10.1155%2f2016%2f6597970&partnerID=40&md5=448eaee8f9607d55769266e9b8dc8db3
dc.relationInvestigadores
dc.relationEstudiantes
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourceDisease Markers
dc.subjectaminotransferase
dc.subjectautoantibody
dc.subjectbilirubin
dc.subjectvasculotropin receptor 3
dc.subjectautoantibody
dc.subjectbilirubin
dc.subjectFgfr3 protein, mouse
dc.subjectfibroblast growth factor receptor 3
dc.subjecttumor antigen
dc.subjectanimal experiment
dc.subjectanimal tissue
dc.subjectantibody blood level
dc.subjectantibody detection
dc.subjectArticle
dc.subjectbile duct ligation
dc.subjectbilirubin blood level
dc.subjectcholestasis
dc.subjectcontrolled study
dc.subjectdisease marker
dc.subjectenzyme linked immunosorbent assay
dc.subjectliver disease
dc.subjectliver fibrosis
dc.subjectliver injury
dc.subjectmale
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectrat
dc.subjectanimal
dc.subjectcholestasis
dc.subjectdisease model
dc.subjecthuman
dc.subjectimmunology
dc.subjectmetabolism
dc.subjectWistar rat
dc.subjectAnimals
dc.subjectAntigens, Neoplasm
dc.subjectAutoantibodies
dc.subjectBilirubin
dc.subjectCholestasis
dc.subjectDisease Models, Animal
dc.subjectHumans
dc.subjectLiver Diseases
dc.subjectMale
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectReceptor, Fibroblast Growth Factor, Type 3
dc.subject.classification7 INGENIERÍA Y TECNOLOGÍA
dc.titleDetection of autoantibodies to vascular endothelial growth factor Receptor-3 in bile duct ligated rats and correlations with a panel of traditional markers of liver diseases
dc.typeArtículo
dc.identifier.volume2016
refterms.dateFOA2018-10-18T15:34:07Z


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess